Meta-analysis of the clinical effect and safety of bevacizumab combined with FOLFOX in patients with advanced colorectal cancer
10.3760/cma.j.cn115396-20191215-00233
- VernacularTitle:贝伐珠单抗联合FOLFOX方案治疗进展期结直肠癌的临床疗效和安全性Meta分析
- Author:
Wenlong DU
1
;
Jia WANG
;
Yuanxian GUO
;
Xiaoping YANG
;
Lanning YIN
Author Information
1. 兰州大学第二医院普通外科 730030
- From:
International Journal of Surgery
2020;47(4):245-251,289-290
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To systematically evaluate the clinical effect and safety of bevacizumab combined with FOLFOX regimen in patients with advanced colorectal cancer.Methods:An electronic search of Pubmed, Embase, CNKI and other Chinese and English databases were retried from their inception to December 2018 to identify relevant literatures, by taking "Bevacizumab, FOLFOX, Advanced Colorectal Cancer, Randomized Controlled Trial" as the keywords for retrieval. Patients were divided into a combination group (bevacizumab combined with FOLFOX program) and a control group (using FOLFOX program alone) according to the treatment method, using Revman 5.3 software for meta-analysis.Results:A total of 11 articles, involving 3178 patients, were included with 1599 in the combination group and 1579 in the control group. The objective group response rate ( OR=3.15, 95% CI: 2.25 ~ 4.40, Z=6.71, P<0.000 01) and disease control rate ( OR=2.73, 95% CI: 1.91 ~ 3.90, Z=5.49, P<0.000 1) in combination group were higher than those in the control group. In terms of adverse reactions, the incidence of gastrointestinal reactions in the combination group was higher than that in the control group ( OR=1.29, 95% CI: 1.07~1.55, Z=2.64, P=0.008 ), There was no significant difference in the incidence of liver injury, leukopenia, hypertension, and neurotoxicity between the two groups. Conclusion:Bevacizumab combined with FOLFOX regimen is more effective than FOLFOX regimen for patients with advanced colorectal cancer, but it will increase the risk of gastrointestinal reactions.
